Viewing Study NCT00301223



Ignite Creation Date: 2024-05-05 @ 4:43 PM
Last Modification Date: 2024-10-26 @ 9:23 AM
Study NCT ID: NCT00301223
Status: COMPLETED
Last Update Posted: 2021-01-22
First Post: 2006-03-07

Brief Title: A Study to Assess the Efficacy Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain
Sponsor: Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization: Pfizer

Study Overview

Official Title: An 8-Week Multi-Center Randomized Double Blind Placebo-Controlled Study To Evaluate The Efficacy Safety And Tolerability Of Pregabalin 150mg-600mgDay Using A Flexible Dosing Schedule In The Treatment Of Subjects With Symptoms Of Neuropathic Pain
Status: COMPLETED
Status Verified Date: 2011-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The objective of this study is to evaluate the efficacy safety and tolerability for pregabalin using a flexible optimized dose schedule compared to placebo in relieving the symptoms of neuropathic pain
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None